A recent study reveals that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a major medical journal demonstrates that while obese individuals can lose substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using these medications should be cognizant of the risk of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to original weight within about a year and a half.
Comparing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the results of these new drugs with conventional dieting.
Researchers note that people who lose weight through dieting generally see a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Quick Regain
Nutrition scientists suggest the mode of action of the drugs accounts for the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS suggest the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the therapy should be considered ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Users who have discontinued the jabs describe a intense resurgence of hunger.
"It felt as if a switch that goes on and you become extremely hungry," described an individual.
This challenge is worsened if individuals have not adopted sustainable dietary or behavioural changes during therapy.
Significant Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, experts emphasize that while the jabs are potent agents for weight loss, they are not a magic fix and long-term success hinges on combined lifestyle support.
